NVO
Novo Nordisk A/S
NYSE: NVO · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$42.22
+4.79% today
Updated 2026-04-30
Market cap
$187.21B
P/E ratio
11.70
P/S ratio
0.61x
EPS (TTM)
$3.61
Dividend yield
4.27%
52W range
$35 – $78
Volume
21.0M
Novo Nordisk A/S (NVO) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+3.9%
Last 4 quarters
Revenue YoY growth
-7.6%
Most recent quarter
EPS YoY growth
-4.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-6.8%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-19.9%
2026-02-03
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-03 | $6.04 | +2.4% | $58.93 | $47.19 | -19.9% |
| 2025-11-05 | $4.50 | +6.1% | $48.25 | $46.51 | -3.6% |
| 2025-08-06 | $5.96 | -0.7% | $47.22 | $48.76 | +3.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $5.90 | $6.04 | +2.4% | $79.14B | -7.6% |
| 2025-09-30 | $4.24 | $4.50 | +6.1% | $74.98B | +5.1% |
| 2025-06-30 | $6.00 | $5.96 | -0.7% | $76.86B | +12.9% |
| 2025-03-31 | $6.07 | $6.53 | +7.6% | $78.09B | +19.5% |
| 2024-12-31 | $6.12 | $6.34 | +3.6% | $85.68B | +30.1% |
| 2024-09-30 | $5.92 | $6.12 | +3.4% | $71.31B | +21.4% |
| 2024-06-30 | $0.74 | $0.66 | -10.4% | $68.06B | +25.3% |
| 2024-03-31 | $0.77 | $0.83 | +7.8% | $65.35B | — |
| 2023-12-31 | $0.66 | $0.71 | +7.6% | $65.86B | — |
| 2023-09-30 | $0.69 | $0.73 | +5.8% | $58.73B | — |
| 2023-06-30 | $0.63 | $0.67 | +6.3% | $54.30B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $22.12 | $296.9B | +-3.9% | 29 | high |
| 2027 (E) | $23.80 | $315.2B | +6.1% | 29 | medium |
| 2028 (E) | $25.50 | $337.5B | +7.1% | 29 | medium |
| 2029 (E) | $25.80 | $379.0B | +13.1% | 11 | medium |
| 2030 (E) | $29.20 | $388.2B | +7.0% | 29 | low |
Frequently asked questions
Has Novo Nordisk A/S beaten earnings estimates?
Novo Nordisk A/S has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +3.9% over the last 4 quarters.
How does NVO stock react to earnings?
NVO stock has moved an average of -6.8% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Novo Nordisk A/S's revenue growth rate?
Novo Nordisk A/S reported year-over-year revenue growth of -7.6% in its most recent quarter, with EPS growing -4.7% year-over-year.
What is the expected EPS for NVO in 2026?
Analysts expect Novo Nordisk A/S to report EPS of $22.12 for fiscal year 2026, on revenue of $296.9B, based on estimates from 29 analysts.